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Abstract Objective Along with changes in the ecology system and under the influence of various environmental
factors, the incidence of tumor has been increasing year after year. There is a trend in cancer therapy to move to combined
therapies involving surgery, radiation chemotherapy and gene therapy. Cancer gene therapy in recent years has brought
new opportunities for treatment of tumor. Its advantages include low rate of tolerance, insensitivity to cell cycles, high
specificity and coverage for both primary and metastatic tumors1,2. However, this is a new field of clinical research.
Regarding the correlation among the STAT3, CyclinD1 and P21 genes and tumors, research has focused on their
expression and regulation. This article provides a summary of related research.
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Signal transducers and activators of transcription-3
(STAT3) STAT3 is an acute phase reaction factor in the
interleukin 6 signal transmission and was first purified in
1994. The STAT3 coding gene is located on chromosome
11 in mice and on chromosomes 12 (q13 to q14-1) in the
human. STAT3mRNA (about 5 KB base pairs) is found
mostly in the brain, heart, liver, testosterone and thymus,
but can also be detected in the spleen. STAT3 is widely
present in different types of cells and tissues. It partici⁃
pates in the regulation of cell growth, malignant transfor⁃
mation and apoptosis 3.
Basic structures and functions of STAT3
Three naturally occurring STAT3 isomers (i.e. STAT3
alpha, STAT3 beta and STAT3 γ) coded by the same
gene have been identified in rodents and humans. STAT3
α protein contains 750-795 amino acid molecules weigh⁃
ing about 89-92 kDa. It contains four important func⁃
tion domains: the DNA combining domain, Src homolo⁃
gous function domain, STAT family homologous regions
(C-Con), and transcription activation phosphorylation ar⁃
ea (transactivation domains, TAD) at the C-end.. STAT3 β
molecule weighs about 80-84 kDa and was cloned from
the library of rat fibroblast cloned DNA (CDNA) in
1995. STAT3 alpha and STAT3 β coexist in a variety of
cells, although there is more STAT3 α than STAT3 β in
most cells. In STAT3 mediated transcription, STAT3 β is
a very strong dominant transcription inhibitory factor 4.
STAT3 γ has a molecular weight of 72 kDa and is the
restrictive protein hydrolysis product of STAT3 alpha. It
does not possess the terminal TAD as STAT3 α does and
is considered a dominant negative isomers of STAT3 5. It
has not been well studied. STAT3 is widely expressed in
various types of cells and tissues. Studies in mice with
STAT3 defects show that STAT3 plays indispensable and
important roles in early embryonic development and in
differentiation of the bone marrow cells 6. According to
the research by Lanxiu et al, STAT3 exhibits persistent
high expression in human lung adenocarcinoma 7. In addi⁃
tion, STAT3 also participates in the regulation of cell
growth and differentiation, malignant transformation and
apoptosis suppression 6-8. Among them, STAT3 α is in⁃
volved mainly in cell proliferation and transform, whereas
STAT3 β is more important to granulocyte colony stimu⁃
lating factor mediated cell differentiation. Activated
STAT3 γ is seen mainly in differentiated Neutrophils,
maybe as a pre-proliferin regulating protein hydrolysis in
mature bone marrow cells9.
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Structure and function of the CyclinD1 gene
In 1988, scientists discovered that cyclins (i.e. cell
cycle regulatory proteins) could combine with cell differ⁃
entiation cycle coding proteins and activate protein kinase
to promote cell division. At least 11 types of cliclin have
been found, i.e. A, B1, B2, C, D1, D2, D3, E, F, G and H,
and eight major types have been successfully separated.
There are seven corresponding cell cycle dependent
kinase (CDKs), i.e. CDK1 to 7. Corresponding Cyclins
and CDKs combine to form holoenzymes and to promote
cell division. In different phases of the cell cycle, different
Cyclins and CDKs play different roles. There are three
sub-types in CyclinD: D1, D2 and D3, whose expression
depends on induction by various growth factors. CyclinD
first appears during mid G1 phase and increases during
the transition from G1 to S phase. As long as external
division stimulation persists, CyclinD expression will
continue throughout the entire cell cycle. On ther other
hand, when external division stimulation stops, CyclinD1
synthesis terminates, leading to exit from the cell cycle.
CyclinD1 gene is located on chromosome 11 q13, with a
length of about 120 KB and a gene span of about 15 KB.
The gene contains five exons, coding a protein of 295 amino
acids with a molecular weight of 34 KD. In eukaryotic
cell division, DNA synthesis must be initiated via G1-S
phase transition, and mitotic period must starts with
G2-M phase transition. CyclinD1 is critically important
to the G1 phase. CyclinD1 appears to form a complex
with CDK4 and CDK6 complex formation and is activated
as the CDK activation kinase is activated. Together with
CyclinE/CDK2 complex, this activated complex phosphor⁃
ylates the RB, releases the transcription factor E2F,
drives the cell to enter S phase from G1 phase, and thus
promotes cell proliferation. The p-Rb, which is in a low
phosphorylation state (function form) in G1 phase,
combines with the E2F transcription factor and inhibits
its activity, thus inhibiting gene transcription of the
protein needed to enter the S phase. When external
proliferation division signals (such as growth factors)
combine with their corresponding receptors, the conse⁃
quential signal transmission promotes CyclinD1 gene
expression. CyclinD1 over-expression can lead to early
implementation of phosphorylation modification of p-Rb
protein, and accelerate the G1-S phase transition process.
When tumor-suppressor genes are missing or not expressed
due to mutations, CyclinD1 becomes dominant with
increased combination with CDK4, leading to excessive
stimulation of cell division and uncontrolled cell growth,
or the formation of tumor. Some scholars believe that
CyclinD1 protein is over-expressed in breast, esophagus,
stomach, liver and head and neck cancers 10.In their
studies on CyclinD1 expression in hypopharyngeal carci⁃
noma, Xing Haijie et al 11 showed that CyclinD1 expression
and metastasis, sensitivity to chemotherapy and prognosis
are closely related.
Structure and function of P21
Of the phosphorylase and cyclin-dependent kinase
inhibitor (DCI) family members, P21 is the first to be
found. P21 is a single copy gene, located on the chromo⁃
some 6 short arm (6 P21. 2) 12. Its DNA length is 85 KB
and there are three exons of 68 BP, 450 BP and 1600 BP
in length. Translation start signal is located in the second
exon, whose CDNA is about 2.1 KB long 1, 2. There are
two shared P53 combining segments upstream from the
P21 genetic encoding area by 2.4 KB and greater than 8
KB, and one weak P53 combining segment 75 nucleo⁃
tides upstream. There is a combining segment for MYOD
(a myogenic transcription factor) about 1000-2000 nucle⁃
otide upstream, and a combining segment for Sp1 50-104
nucleotide upstream. The P21 protein has 164 amino
acids, rich in argentine, with a molecular weight of 21
kD, Between the 13th and 41st amino acids, there is a
homocysteine-rich section C (X) 4 C (X) and C (X) 16 C
constituting a zinc finger domain. The 164th-124th
amino acids from the C end bind to proliferating cell
nuclear antigen (PCNA) and the middle 49th-72nd amino
acids bind to CDK2. There is a nuclear locating signal
among the C 140th-163rd amino acids, making it a nuclear
protein 12,13. P21 is presently known to have the most
broad kinase inhibition activity of all cell cycle inhibitory
proteins. Its 21st-26th and 49th-72nd amino acids bind
to Cyclin and CDK respectively to de-activate kinase
activity of the Cyclin-CDK complex.P21 can bind to almost
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every Cyclin-CDK complex and broadly inhibit all kinds of
Cyclin-CDK compounds, including CyclinD1-CDK4,
CyclinE-CDK2 and CyclinA-CDK2, although its inhibi⁃
tion on CyclinB related complexes is weak 13. P21 inhibits
CyclinD1-CDK4 and CyclinE-CDK2 activities and
prevents Rb protein from phosphorylation, thus stopping
the cell cycle in the G1 phase 13. P21 can inhibit binding
between PCNA and DNA polymerase 6. PCNA is a
subsidiary factors in DNA polymerases and, together with
replication factor C (RFC), recognizes the primer-template
complex and facilitate locating polymerase 6. It also
enhances advance of PCNA polymerase in the process of
extension. Binding of PCNA with 40 amino acid residues
on the P21C end covers its functional zone (without
damaging its spatial conformation) and prevents it from
forming compounds with polymerases 6, or prevents DNA
holoenzymes from sliding on DNA chains, thus disrupting
DNA replication 3. P21 can inhibit stress activated
protein kinase (SAPK) activity. SAPK is an important
member of the MAP family and an important part of
signaling pathways. When cells are under stress, P21 N
end combines with SAPK, inhibits its activity, prevents
c-jun from phosphorylation and Ap-1 from activation,
thus participating in regulation of the signal transmission
cascade system in cell stress state 14. In vitro studies show
that low concentration P21 stimulates the phosphorylation
of relevant functional groups, promoting the G1-S conver⁃
sion; whereas high concentration P21 inhibits tetramers’
kinase reaction, leading to pause of cell cycle 15. P21’s
collaborative role with activation kinase signals its other
functions. Zhang et al 15 speculate that, as a CDK aggre⁃
gation factor, P21 may up-regulate its activity.
STAT3 signal transduction and transcription activa⁃
tion mechanisms and P21 mechanisms
STAT3 signal transduction and transcription activation
mechanisms
Details in transcription mechanism of STAT3 signal
transduction and activation have not yet been clarified.
The general process is probably like this: CK receptors
(IL-2 receptor, IL-5 receptors, interferon alpha receptors,
growth factor receptor, etc) combine with their ligands
to form homologous or heterogenic receptor complex; in
the cytoplasm these complexes combine with JAKS to
produce or recruit STAT3 in the cytoplasm and to cause
phosphorylation activation of its tyrosine; the activated
STAT3 leaves the receptors, interacts with tyrosine phos⁃
phorylation sites (Y17 and Y705) through the intermo⁃
lecular SH2 domain, and forms homologous or hetero⁃
genic daughter dimmers (STAT1/STAT3 or STAT2/
STAT3) in the cytoplasm which quickly move into the
nuclear and bind with the promoter of particular genes to
activate transcription 5. Through this process, STAT3
turns the short-term cytoplasm signal triggered by CK
into long-term gene expression changes, thus regulating
various physiological functions of the cell. STAT3 can
promote expression of cancer genes such as BCL-xl and
negate effects of some chemotherapy drugs that act on the
apoptosis pathway. With advances of research, it has
been found that STAT3 signal pathways, through regula⁃
tion of transcription of downstream target genes, are
involved in tumor cell proliferation, apoptosis, angio⁃
genesis, and immune evasion and more. Therefore, inhi⁃
bition of STAT3 activation can not only prevent cancer
development, but also enhance tumor cell sensitivity to
radiation and chemotherapy agents.
P21 activity mechanisms
Dependence on P53 pathway
Participation in P53 mediated cell DNA damage
responses: Many studies have shown that P21 participates
in the cell cycle block reaction to DNA damage 12-16. Using
differential hybrid technique, EI-Deiry et al 13 isolated
the P21gene corresponding to wild type intracellular P21
that was activated by P53, and combined the P21 promoter
containing the P53 binding sites with the report gene to
construct report gene expression plasmid that could be
induced by P53. In cell DNA damage, high P53 and P21
expression is frequently seen in P53 +/+ cells, but high
P21 expression is not seen in P53-/-cells with no G1
phase pause 17. In vitro studies have shown that the rates
of P53 and P21 proteins expression in primary nasopha⁃
ryngeal carcinoma tissue are positively correlated18.
Research shows that cell DNA damage induces P53
expression, which regulates P21 expression. As a P53’s
downstream intermediary, P21 implements some of P53
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functions by inhibiting Cyclin-CDK complex and PCNA,
which leads to G1 phase pause.
Involvement in cellar functions via non-P53 dependent
pathways
In vitro studies show that P53-/-cell lines can be
induced to express P21 when stimulated by some growth
factors (PDGF, EGF), OA, TPA, VitD3, g-csf, IL-6,
IFN-γ and TGF-β, indicating that P21 possesses
non-P53 pathway dependent regulation mechanisms. In
vivo studies also support the view. In order to understand
the non-P53 pathway dependent P21 expression, ZENG
et al 19blocked transcription using transcription inhibitors
AMD (actinomycin D) and found that induction of P21
expression by TPA and doxorubicin disappeared while
that by OA decreased, indicating that induction of P21
expression by TPA and doxorubicin takes place at tran⁃
scription level and that by OA is through post-translational
regulation mechanisms.
These studies show that P21, as an inducible growth
inhibitor, can lead cells away from the cell cycle to differ⁃
entiation and plays an important role in individual devel⁃
opment. P21 responds to both cellular signal (P53) and
extracellular signals (growth factor, etc) and is involved
in a variety of functional activities in cells.
STAT3, cyclinD1, P21 and tumor
STAT3 and tumor
Structurally activated STAT protein exists in speci⁃
mens of most human cancers (e.g. multiple myeloma,
lymphoma, breast, head and neck epithelial cell tumor,
melanoma, prostate cancer, etc) and in cancer cell lines,
of which STAT3 is the most common 20. Activated STAT3
plays an important regulatory role in the formation,
growth and apoptotic inhibition in tumor cells. STAT3
structural activation can be detected in blood samples
from patients with a variety of leukemia. Tyrosine phos⁃
phorylation in STAT3 is seen in 74% of peripheral blood
samples from patients with acute myeloid leukemia.
Takem Oto et al 21found STAT3 activation in peripheral
blood mononucleocytes (PBMC) in 12 adult patients with
T cell leukemia, with the longest lasting for six months.
They believe that structural activation of STAT3 is related
to the replication and proliferation of leukemia cells.
Tyrosine phosphorylated STAT3 is not found in chronic
lymphocytic leukemia, although serine structural activa⁃
tion in STAT3 is detected in all patients with chronic
lymphocytic leukemia. Persistent serine structural activa⁃
tion in STAT3 is commonly seen in chronic lymphocyt⁃
ic leukemia, although only occasionally seen in other
types of leukemia. Li Xiaoming et al 22 have shown that
transfection of State3ASODN using antisense technology
can inhibit proliferation of Hep-2 cells in laryngeal carci⁃
noma and promote their apoptosis. It can also regulate
cyclin through down-regulating expression of relevant
proteins and increase tumor sensitivity to radiotherapy,
thus improving radiotherapy outcomes. In addition to
blocking STAT3 pathway and inhibiting tumor cell prolif⁃
eration, State3AS-ODN transfected Hep-2 also blocks
hypoxia induced expression of HIF-1alpha and VEGF,
thereby reducing the tumor cell hypoxia adaptability and
tumor angiogenesis, inhibiting tumor progression 23.
CyclinD1 and tumor
CyclinD1 was first confirmed as a protocarcinogenic
gene in human thyroid tumor in 1991, followed by reports
of its over-expression in most human tumors including
laryngeal cancer. Studies show that expression of CyclinD1
protein in laryngeal carcinoma is positively correlated
with STAT3, and that STAT3 participates in laryngeal
cancer formation by promoting CyclinD1 protein expres⁃
sion 24. Lisui et al 25 tested CyclinD1 expression using
immunohistochemical techniques in 79 cases of ovarian
tumors and found that its expression rate in benign, interim
and malignant tumors was 72.7%, 69.6% and 32.4%,
respectively, indicating that CyclinD1 over-expression
could be used as an indicator to identify benign or malig⁃
nant ovarian tumors. Through studying prognostic factors
in colorectal cancer, Schwandner et al 26 believe that
CyclinD1 is not significantly associated with prognosis
and question if CyclinD1 is a prognostic factor. Bukholm
et at 27 tested CyclinD1 using immunohistochemical tech⁃
nology in 93 cases of colon cancer. CyclinD1 was positive
in only 8 cases (8.6%, strong positive in 4 and weak posi⁃
tive in 4). The authors believe that CyclinD1 over-expres⁃
sion is not important in pathogenesis in colon tumors. Li
et al 28 tested expression of CyclinD1 using immunohisto⁃
chemical technology in normal pancreas tissue (n=10),
pancreatic epithelial tumors (n=12) and pancreatic cancer
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(n=47) showing a positive rate of 0.0% , 50.0% and
74.5% , respectively. Analysis of results shows that
CyclinD1 in pancreatic cancer correlates to cell prolifera⁃
tion and degree of differentiation, but not to tumor size,
metastasis or one year survival.
P21 and tumor
P21’s role in resistance to tumor: In anaplastic mela⁃
noma cells, SV40 transformed melanoma cells and meta⁃
static melanoma, P21 expression progressively decreases,
linking low P21 expression to the initiation, development
and metastasis of the tumor. In vitro studies also show
that P21 may be involved in the antitumor process. In
testing P21 expression by immunohistochestry in 198
patients with oral carcinoma, Huang Jian et al 29 found
that it was significantly lower than that of normal tissue
in 81.82% of the patients, indicating a change with
P21genes in oral cancer cells, leading to loss of inhibi⁃
tion of cell proliferation, which in turn promotes develop⁃
ment of tumor. When BRCA1 is transfected into human
cancer cells, it can transform via non-P53 dependent
pathways and activate P21 expression, causing a pause in
the S phase, which is not seen in P21-/-cell lines.
Mutated BRCA1 does not activate P21 expression nor
cell cycle blockage, indicating that P21 is involved in
tumor inhibition by BRCA1 30. P21 is also involved in the
anti-tumor process by the antitumor drug taxol 31. P53+/+
cell lines express P21 and wild type P53 protein after taxol
treatment; even P53-/- PC3M cell lines demonstrate
P21 expression after taxol treatment, showing that P21
participates in taxol’s cancer-fighting effects via
both P53 dependent and non-P53 dependent pathways.
P21 DNA polymorphisms and cancer predisposition:
P21 mutations are negative in most tumor tissues. Its
mutations are only occasionally reported 30. Studies have
shown two P21 gene polymorphisms, which are related to
susceptibility to breast cancer, lung cancer, soft tissue
sarcomas, prostate cancer, head and neck aqueous cell
carcinoma 32. One P21 polymorphism is at the 31st codon
on exon 2, i.e. a C -> A change in nucleotides (serine
replaced by arginine), and the other is at the 20th codon
from the 3’end on exon 3, i.e. a C->T change in nucleo⁃
tide. P21 polymorphisms have not been seen in those
with P53 mutation 32. In tumor tissues of 96 cases without
P53 mutations, 18.8% showed the two P21 gene polymor⁃
phisms in the 3’non-transcription area, higher than the
control group (P < 0.05), indicating that P21 polymor⁃
phism is important in enhancing predisposition to some
tumors 33. Other P21 genes, as well as the P53 binding
site gene, show no mutations or polymorphism. Studies
have showed that several genes in the 3' non-transcrip⁃
tion area are important in cell proliferation, differentia⁃
tion, tumor suppression and tumor metastasis inhibition 33.
This area also contains the DNA sequence that deter⁃
mines mRNA stability and degradation rate. Because the
two P21 polymorphisms are separated from each other, it
is speculated that they are synergetic in influencing cell
phenotype. The 3’non-transcription area may be involved
in P21 mRNA rapid degradation. P21 mRNA containing
the 31st codon polymorphism may be more stable because
of its synergetic action with the 3' UTR polymorphism.
This mRNA with extended half-life may interfere with
the G1 phase pause induced by DNA damage, increasing
cell sensitivity to DNA damage and, as a result, predispo⁃
sition to tumor in those with P21 polymorphisms 32.
Problems and prospect
Large amount of research has been focused on STAT3
since its discovery in 1994 with noticeable progress, but
our knowledge of STAT3 remains limited. An example of
unclear points regarding STAT3 is the mechanisms in
regulating STAT3α/STAT3β ratio in different cells and
the physiological processes affected by this ratio and the
significance. Because early STAT3 research used cultured
cells, it is not clear if the results reflect STAT3 activation
specifically in various cells and tissues. These all need to
be further explored in future studies of STAT3.
As a recessive oncogene, CyclinD1 gene can cause cell
transformation activation in collaboration with activated
ras or myc gene. On the other hand, tumor suppressor
genes P21 and P53 can regulate CyclinD1 activity. In
most tumors, CyclinD1 gene amplification and/or increased
expression are present. While the clinical significance of
this remains to be studied, CyclinD1 is expected to become
a new target in cancer gene therapy as transfection of
colon and esophageal cancer cells with antisense
CyclinD1cDNA leads to increased tumor doubling time
and loss of tumorigenicity.
P21 is a cyclin with the broadest kinase inhibition
activity known to us so far. , Through P53dependent or
non-P53 dependent pathways, it participates in regulation
of cellular functions including cell growth, development,
··23
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differentiation, aging and DNA damage repair. Its broad
inhibition on CDK implies its role in tumor initiation and
development. Research has also shown that its polymor⁃
phisms and positive expression are related to a variety of
tumor biological behaviors. Recent research further
shows the hope for P21 gene therapy to fundamentally
change cancer treatment strategies. But whether P21 is
tissue specific, to which the tumor it is specific, the rela⁃
tionship between P21 and non-P53 dependent regulatory
factors and its effects on the tumor remain to be further
studied.
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